| Title: |
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab |
| Authors: |
Rossi, Settimio; Gesualdo, Carlo; Marano, Ernesto; Perrotta, Raffaele; Trotta, Maria Consiglia; Del Giudice, Antonio; Simonelli, Francesca |
| Source: |
Frontiers in Medicine ; volume 11 ; ISSN 2296-858X |
| Publisher Information: |
Frontiers Media SA |
| Publication Year: |
2025 |
| Collection: |
Frontiers (Publisher - via CrossRef) |
| Description: |
Background Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy. The aim of this study is to provide the real-life anatomical-functional and safety results, after 1 year of treatment experience with Brolucizumab. Methods This is a retrospective observational real-life study in which 44 patients (44 eyes) diagnosed with nAMD and treated with Brolucizumab were enrolled. We identified two groups: group 1 (24 treatment-naïve eyes) that received a loading dose of 3 monthly intravitreal injections of Broluciziumab 6 mg (0.05 mL solution) + Q8w/Q12w regimen, and a Group 2 (20 non-naïve eyes) which performed 1 injection + ProReNata (PRN) scheme. Monthly, all participants underwent comprehensive ophthalmological evaluation until 12 months follow-up. Results We observed a significant improvement in best corrected visual acuity (39 ± 15 L vs. 30 ± 17 L; p < 0.01) and central retinal thickness (265 ± 89 μ vs. 360 ± 129 μ; p < 0.0001) at the end of follow-up without any differences between treatment-naïve and non-naïve patients. These results were obtained with a low number of injections (3.7 ± 1.9) with only one case of intraocular drug-related adverse event. Finally, the presence of subretinal hyperreflective material correlates with lower visual recovery. Discussion Our findings highlight the efficacy of Brolucizumab in managing wet-AMD and suggest its role for long-term efficacy in stabilizing retinal exudation and fluid accumulation, resulting in improved visual prognosis. |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| DOI: |
10.3389/fmed.2024.1467160 |
| DOI: |
10.3389/fmed.2024.1467160/full |
| Availability: |
https://doi.org/10.3389/fmed.2024.1467160; https://www.frontiersin.org/articles/10.3389/fmed.2024.1467160/full |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.8D680F24 |
| Database: |
BASE |